All In Biotech

Drug Trial Radar · NCT01197053

Epicutaneous Immunotherapy in Peanut Allergy in Children

ARACHILD: A Multicentric, Double Blind Placebo-controlled Pilot Protocol to Study the Efficacy and Safety of an Epicutaneous Immunotherapy in Children Allergic to Peanut

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Aug 2010

Primary completion

Feb 2015

Study completion Apr 2015

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
DBV Technologies; URC-CIC Paris Descartes Necker Cochin
First posted
Sep 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 5 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims at showing that Epicutaneous Immunotherapy with peanut proteins is safe and efficacious for desensitizing children with peanut allergy.

Conditions

  • Peanut Allergy

Interventions

  • Epicutaneous ImmunotherapyBiological

    100 mcg peanut proteins (active arm) applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm

  • placebo of peanutBiological

    placebo applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients able to consume >1000 mg of peanut proteins symptom-freeTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hopital Necker

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.